Ethical Dilemma with Stakeholders
You're the CEO of a pharmaceutical company. Your best-selling drug ($2B annual revenue, used by 4 million patients for chronic pain) has…
You have a patient safety issue, not a PR issue. The 6 month regulatory reporting timeline is the formal process, not the ethical or legal obligation to act now. Waiting for more data while patients continue to be exposed is criminal negligence exposure, not risk mitigation.Read the full answer
As CEO, my primary fiduciary and ethical duty is to patients, regulators, and long-term shareholder value. The "6-month reporting timeline" cited by legal is almost certainly a misunderstanding of regulatory processes (likely conflating initial adverse event reporting with full label amendment review).Read the full answer